Letters NICE transparency

Let cost effectiveness models be open to scrutiny

BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39360.379664.BE (Published 11 October 2007) Cite this as: BMJ 2007;335:735
  1. Chris Poole, director1,
  2. Samir Agrawal, consultant haematologist2,
  3. Craig J Currie, honorary senior research fellow3
  1. 1Pharmatelligence LLP, Cardiff MediCentre, Cardiff
  2. 2Department of Haematological Oncology, St Bartholomew's Hospital, London
  3. 3Department of Medicine, Cardiff University, Cardiff
  1. drchrispoole@googlemail.com

    In light of the recent ruling over the National Institute for Health and Clinical Excellence's (NICE) decision on donezepil,1 2 we wish to comment on the adversarial system of drug evaluation and the inadequacy of NICE providing read-only versions of cost effectiveness models for the purposes of reviewing their decisions.

    The assertion that “[NICE] is not in a position to deal with the …

    View Full Text

    Sign in

    Log in through your institution